News Hub | News Direct

Professional Services

Architecture CRM/Customer Service Consulting Government & Policy Human Resources Intellectual Property/Trademark/Patent Law Legal
Article thumbnail News Release

Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204

Global Markets News

Shares of Silexion Therapeutics (NASDAQ:SLXN) are seeing significatnly today after the company announced promising new preclinical data for its next-generation siRNA candidate, SIL-204. The stock saw a significant initial of price spike of over 50% in pre-market activity as investors responded to the latest developments in Silexion's RNA interference (RNAi) platform, which targets KRAS-driven cancers. As of now, volume is at record highs, currently standing at over 50 million shares today. The company revealed that SIL-204, an extended-release microparticle formulation, demonstrated substantial tumor reduction and necrosis in mouse models of pancreatic cancer bearing the KRAS G12D mutation—one of the most common mutations found in pancreatic cancer patients. This latest data builds on a string of recent successes for Silexion, including its September 24 announcement of results from the Phase 2 trial for its first-generation product, LODER™, which showed significant improvements in tumor resectability among non-resectable pancreatic cancer patients. Alongside the new preclinical results, Silexion has recently reported plans to begin toxicology studies for SIL-204 in preparation for Phase 2/3 clinical trials expected to commence in the first half of 2026. The company is also expanding the application of its siRNA technology to colorectal cancer models, reflecting its broader ambitions to target multiple KRAS-driven cancers, which are notoriously difficult to treat with conventional therapies. While stock price has pulled back since premarket, The spike in Silexion’s market activity as marked by these record high volumes (according to market data) may highlight the growing market interest in the company’s novel approach to tackling cancers with high unmet medical needs, particularly its focus on KRAS mutations, which are common across a variety of aggressive cancers, including pancreatic and colorectal cancer. Silexion’s continued momentum in the precision oncology space potentially positions it as a leading player in the development of next-generation RNAi therapies. With its promising pipeline and recent positive developments, the company seems to be gaining attention as it advances toward clinical trials that could offer new hope for patients battling some of the deadliest cancers. Click here to read Silexion's full announcement *** This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

October 01, 2024 11:47 AM Eastern Daylight Time

Article thumbnail News Release

Methode Electronics Inc. Has Been Implicated In A Securities Fraud Class Action Lawsuit – Here's How Investors Can Get More Information

Benzinga

By Meg Flippin, Benzinga Methode Electronics Inc. (NYSE: MEI) is under the spotlight amid a class action lawsuit filed in the United States District Court for the Northern District of Illinois against the company and former executives for allegedly engaging in securities fraud. The action, Marie Salem v. Methode Electronics Inc., et al., impacts investors who purchased or acquired shares of Methode Electronics between June 23, 2022, and Mar. 6, 2024. Methode is a Chicago-based designer and manufacturer of custom-engineered parts used in transportation, cloud computing infrastructure, construction, consumer appliances and medical devices. Most of its revenue is derived from its automotive segment, which had reportedly been humming along until 2020. With car manufacturers using fewer designs featuring buttons and knobs, favoring display screens and infotainment, Methode shifted its focus. Methode opted to move away from its low-mix but high-margin parts business into specialized components targeted at electric vehicle manufacturers instead of traditional car companies, which appeared to promise to bring higher margins and more sales – but that transition proved to be rocky, and the company allegedly hid its woes from investors, leading to the class action lawsuit. Transition To Speciality Components Rocky According to the lawsuit, during the transition period, the company made materially false and/or misleading statements and failed to disclose material adverse facts about operations and its prospects. The lawsuit points specifically to the company misleading investors or failing to disclose to them the operational, logistics and personnel problems that plagued the transition. What’s more, the lawsuit contends Methode did not disclose setbacks at its Monterrey facility during the transition caused by turnover, poor operational decisions, issues with vendors and supply-chain snafus that led to production planning delays, inventory shortages and what the lawsuit calls “botched” execution of the company’s plan. On top of that, the company incurred increased costs and delayed launches as it attempted to retool the plant to produce the specialty components. All told, the lawsuit states the “company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.” The lawsuit explains that this all started showing up in March 2023 when the company’s automotive unit missed sales targets for the third quarter and lowered its full-year 2023 diluted earnings per share guidance, sending the stock down 13% over the course of multiple trading sessions. The bloodletting didn’t stop there, with the company announcing a series of earnings misses in the subsequent quarters which weighed on the stock. Finally, in March 2024 when reporting its third-quarter 2024 results, Methode announced its automotive segment suffered an $11 million loss from operations, prompting it to withdraw its prior guidance citing “operational challenges” at its Monterrey facility. The company told investors its prior guidance should no longer be relied upon. To improve operations, the company announced it was cutting its headcount and discretionary expenses and is unloading non-core assets. On a conference call at the time to discuss results, the company’s new chief executive officer, Avinash Avula, said Methode’s sales for the third quarter were down $21 million year-over-year “entirely [attributable to] our Auto segment.” That drove the stock down about 31%. Here’s How Methode Investors With Losses Can Find Out More Information About Their Rights Kessler Topaz Meltzer & Check, LLP has earned a reputation for prosecuting class actions in state and federal courts throughout the United States and globally. It reports that it has successfully recovered billions of dollars for victims of fraud and other corporate misconduct. The firm is encouraging Methode investors who have suffered significant losses to directly contact it for more information. To potentially qualify as a lead plaintiff in the Methode class action lawsuit, investors must take action no later than October 25, 2024. They can move the court to serve as lead plaintiff either through Kessler Topaz Meltzer & Check, LLP, or other legal counsel. Alternatively, investors can choose to do nothing and remain as absent class members. A lead plaintiff is a representative party who acts on behalf of all class members in the litigation. This individual or small group of investors typically has the largest financial interest and is considered adequate and typical of the proposed class of investors. The lead plaintiff also selects legal counsel to represent both the lead plaintiff and the class. If the court approves these attorneys, they become lead or class counsel. Applying to become a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit. CLICK HERE to submit your Methode losses or contact an attorney to discuss your rights: Jonathan Naji, Esq. (484) 270-1453 or email at info@ktmc.com. Link also available here: https://www.ktmc.com/new-cases/methode-electronics-inc?utm_source=benzinga&utm_medium=article&utm_campaign=mei&mktm=bzb Featured photo by Timothy Dykes on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 27, 2024 08:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

drive21, Van Wagner Collaborate to Elevate In-Venue Branding and Fan Engagement Across College Athletics

drive21

drive21, a leader in experiential design and marketing solutions, today announced a strategic relationship with leading collegiate athletics marketing agency, Van Wagner to become a preferred experiential graphic design and implementation provider for Van Wagner. Van Wagner is recognized for its expertise in collegiate sponsorship sales and multi-media rights and will collaborate with drive21 to redefine branding strategies, drive revenue growth, and create Name, Image and Likeness (NIL) execution opportunities in the collegiate sports industry. Through this relationship, Van Wagner’s collegiate clients will be afforded advantageous pricing and access to drive21’s suite of services to provide innovative branding and design solutions across their venues; driving innovative solutions that bridge the gap between brand aspirations and reality, creating immersive environments that resonate with audiences and drive tangible business results. "This relationship represents a significant step forward in our mission to transform sports and entertainment venues into impactful environments that are also powerful marketing tools," said Warren Godridge, drive21 Founder and President. "By collaborating with Van Wagner, we can leverage our creativity and expertise to deliver a consistent brand experience across all venues, enhancing the value for brands, universities, and fans alike." “Traditional approaches often focus solely on aesthetics and overlook the potential to maximize partnership, sponsorship and NIL opportunities, leaving untapped value on the table” said John Libro, Head of Sports and Entertainment at drive21. “Working with Van Wagner College will allow us to push the boundaries of experiential design and transform collegiate athletic facilities into dynamic revenue-generating tools that engage fans and drive real business growth.” This relationship may also offer an even more comprehensive solution to collegiate clients by providing new NIL revenue streams. Through this collaboration with drive21, a portion of the facility’s expenditure can be reallocated to the universities’ NIL efforts. This allows universities to offer a more engaging experience for athletes and fans while creating dynamic environments supporting athletic performance, fan engagement and brand partnerships. "drive21’s ability to seamlessly integrate brand experiences into our facilities is a game-changer for our clients,” said Mark Donley, Chief Revenue Officer at Van Wagner College. “Through our arrangement with drive21, our university clients have an opportunity to access the expertise of drive21 to not only enhance their facilities but also ensure a consistent and high-quality experience for a variety of initiatives at an advantageous rate. It's truly a win-win-win scenario." The first major joint effort was a collaboration at Florida International University for the brand implementation of the newly named Pitbull Stadium. drive21 and Van Wagner played a key role in creating cohesive branding for the first college athletic venue named after a musician, exampling the transformative potential of experiential design and strategic branding. To learn more about the partnership, or drive21’s sports, entertainment and hospitality solutions, please visit www.drive21.com. About drive21 drive21 elevates the sports, entertainment, and hospitality industries by delivering one-of-a-kind branded venue experiences. A leader in experiential design and marketing solutions, drive21 bridges the gap between imagination and reality to deliver functional and impactful environments through design, fabrication, implementation, and holistic project management. Servicing organizations including MLB, MLS and NCAA institutions, drive21 helps its clients maximize partnership and sponsorship revenue and turns ordinary environments into extraordinary works of art. For more information, visit www.drive21.com. About Van Wagner Van Wagner is a leading sports advertising and entertainment agency with global expertise in filmed and live entertainment, sponsorship sales, multi-media rights, and aerial advertising. Van Wagner creates, advises, and sells for world-class teams, leagues, brands, and properties. An innovator in the sports and media business, Van Wagner is a global leader in high-impact broadcast visible signage throughout the MLB, NBA, NCAA, and international soccer, sponsorships sales, college multi-media rights, and in-venue content production at the world’s biggest sporting events. For more information, visit www.vanwagner.com. Contact Details Hot Paper Lantern Jackson Gaskins jgaskins@hotpaperlantern.com Company Website https://drive21.com

September 25, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

BestGrowthStocks.Com Issues a Comprehensive Analysis of Kaival Brands Merger with Global Logistics Provider Delta Corporation

Kaival Brands Innovations Group Inc (KAVL)

NEW YORK, NY / NewsDirect / September 25th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued an in-depth analysis of Kaival Brands Merger with Global Logistics Provider Delta Corp. Holdings Limited. Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) has garnered significant investor attention following this transformational merger announcement with Delta. Best Growth Stock's full report offers an in-depth analysis of Delta and Kaival's operations, competitive advantages, potential catalysts, growth drivers, financials, and more. Access this full analysis free here: https://bestgrowthstocks.com/access-kaival-delta-merger-analysis/ About Kaival Brands Based in Grant-Valkaria, Florida, Kaival Brands is a company focused on incubating and commercializing innovative products into mature and dominant brands, with a current focus on the distribution of electronic nicotine delivery systems (ENDS) also known as “e-cigarettes” for use by customers 21 years and older. Our business plan is to seek to diversify into distributing other nicotine and non-nicotine delivery system products (including those related to hemp-derived cannabidiol (known as CBD) products). Kaival Brands and Philip Morris Products S.A. (via sublicense from Kaival Brands) are the exclusive global distributors of all products manufactured by Bidi Vapor LLC. Based in Melbourne, Florida, Bidi Vapor maintains a commitment to responsible, adult-focused marketing, supporting age-verification standards and sustainability through its BIDI® Cares recycling program. Bidi Vapor's premier device, the BIDI® Stick, which is distributed exclusively by Kaival Brands, is a premium product made with high-quality components, a UL-certified battery and technology designed to deliver a consistent vaping experience for adult smokers 21 and over. Learn more about Kaival Brands at https://ir.kaivalbrands.com/overview/default.aspx. About Delta Delta Corp Holdings Limited is a fully integrated global enterprise engaged in logistics, fuel supply, and asset management services, primarily supporting the international supply chains of commodity, energy, and capital goods producers. With its headquarters in London, Delta operates through three main segments: Bulk Logistics, Energy Logistics, and Asset Management. The company also maintains executive offices in Dubai and New York, and boasts a significant commercial presence in Singapore, Rotterdam, New Delhi, and Mumbai. For more information, please see Delta’s website at www.wearedelta.com. About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Media Contact Best Growth Stocks Senior Editor: Steve Macalbry Editor@BestGrowthStocks.Com SOURCE: BestGrowthStocks.Com Contact Details Media Source LLC Steve Macalbry +1 989-274-7778 editor@bestgrowthstocks.com Company Website https://bestgrowthstocks.com/

September 25, 2024 07:00 AM Eastern Daylight Time

Article thumbnail News Release

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

Article thumbnail News Release

Join Benchmark International's Exclusive Webinar "Seller Motivation: What Goes Into the Decision to Sell?"

Benchmark International

Are you considering selling your business? Deciding when and why to sell is one of the most significant decisions you’ll ever make as a business owner. While maximizing financial proceeds is often at the forefront of these decisions, it’s essential to recognize that it’s not the only factor. Life circumstances, time with family, and other qualitative considerations can often outweigh financial gain. To help you navigate this complex process, we invite you to join our upcoming webinar: Seller Motivation: What Goes Into The Decision To Sell? Space is filling up fast, so register today! Why You Should Register Selling a business is about more than just crunching the numbers. In this exclusive webinar, you’ll gain valuable insights into the full spectrum of motivations that drive business owners to sell. Understanding these motivations can help you make a well-rounded and informed decision about your business’s future. This webinar is a must-attend for business owners contemplating the sale of their business, particularly in today’s strong but disciplined market. By attending, you’ll be better equipped to evaluate both the financial and personal factors that play a crucial role in this life-changing decision. Whether you’re focused on securing a comfortable financial future or prioritizing time with loved ones, the information presented will help you weigh these considerations effectively. Spots are limited, so don’t miss this opportunity to secure your spot. What You’ll Learn This webinar offers actionable insights into the decision-making process for business owners. Here’s what you can expect to learn: The wide range of reasons why business owners choose to sell, beyond just financial incentives How personal life events, such as family needs and future aspirations, can influence your decision A look at the current M&A market and how buyers are approaching valuations How to balance personal and financial goals using the concept of indifference curves, which help weigh non-monetary values like time with family against financial returns By attending, you’ll gain the tools to make a decision that aligns with your long-term vision—both personally and financially. Spots Are Filling Fast – Register Now! If you’re ready to gain clarity on your motivations for selling and align your decision with both your personal and financial goals, this is the webinar for you. Don’t miss out—register now and take the first step toward making a well-informed, strategic decision about the future of your business. ABOUT BENCHMARK INTERNATIONAL: Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $11 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive Privately-held M&A Advisor in the World by Pitchbook and Refinitiv's Global League Tables. Contact Details Brittney Zoeller +1 813-898-2350 zoeller@benchmarkintl.com Company Website https://www.benchmarkintl.com/

September 16, 2024 09:54 AM Eastern Daylight Time

Image
Article thumbnail News Release

Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment

Global Markets News

A new report by PESG Research highlights Nuvectis Pharma's (NASDAQ: NVCT) drug candidate NXP900 and its potential role in the treatment of Non-Small Cell Lung Cancer (NSCLC). The review focuses on NXP900's unique approach to addressing critical challenges in cancer therapy resistance. NXP900 is positioned as a potential significant player in NSCLC treatment, comparing its approach to Summit Therapeutics' ivonescimab. NXP900's mechanism of action targets SRC/YES1 kinases in EGFR and ALK resistant NSCLC patients, offering a novel approach to overcoming treatment resistance. Preclinical studies, as noted in the report, indicate that NXP900 could enhance the efficacy of existing therapies like AstraZeneca's osimertinib (Tagrisso) when used in combination. The report also mentions NXP900's potential beyond NSCLC, including possible applications in other cancers such as squamous cell carcinoma. Context: The Current NSCLC Treatment Landscape The report comes at a time of significant developments in NSCLC treatment. Recently, Summit Therapeutics (NASDAQ: SMMT) made headlines with its drug ivonescimab, which showed promising results in a Phase 3 trial conducted in China. In this trial, ivonescimab outperformed Merck's Keytruda (NYSE: MRK), a current standard of care in many NSCLC cases. This breakthrough has intensified interest in novel approaches to NSCLC treatment, particularly those addressing resistance mechanisms. The report highlights the different approaches being developed to tackle NSCLC. While Summit's ivonescimab targets PD-L1 expression, Nuvectis' NXP900 focuses on EGFR and ALK mutations. The report suggests that this diversity in treatment approaches could be important in providing comprehensive options for NSCLC patients. Nuvectis Pharma's NXP900: Current Status and Potential NXP900 is currently in Phase 1 clinical trials, with a focus on safety and pharmacokinetics evaluations. The report emphasizes the preclinical data supporting NXP900, noting its activity against NSCLC models resistant to standard treatments and its potential synergistic effects when combined with existing therapies. A key feature of NXP900, as highlighted in the report, is its ability to inhibit both catalytic and scaffolding functions of SRC and YES1, which are described as key drivers of cancer cell survival. Implications for Cancer Treatment The Report underscores a trend in oncology: the focus on overcoming treatment resistance. It notes that as patients face progression despite initial responses to immunotherapies or targeted treatments, there's a growing need for novel approaches. NXP900's approach to targeting SRC/YES1 kinases seems is positioned as a unique strategy strategy compared to other emerging therapies. This diversification of approaches could be important in providing multiple avenues to tackle the complex mechanisms of treatment resistance. Conclusion The report provides an in-depth look at Nuvectis Pharma's NXP900, positioning it as a noteworthy development in the field of NSCLC treatment. While acknowledging the early stage of NXP900's development, the report highlights its unique mechanism of action and potential to address treatment resistance. The report suggests that as the landscape of NSCLC treatment continues to evolve, NXP900 represents one of several innovative approaches aiming to improve outcomes for cancer patients. As with all early-stage drug candidates, the full potential of NXP900 will only become clear as it progresses through clinical trials and further research. Click here to review the full report: https://finance.yahoo.com/news/pesg-releases-report-nuvectis-pharma-111500319.html * Please make sure to refer to the full dislcaimers and disclosures linked in the report itself when reading it. *** This news alert may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. *** This news alert is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/fcm9n/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news related to innovative companies and industries and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 16, 2024 08:45 AM Eastern Daylight Time

Article thumbnail News Release

Comcast to Expand Fiber Broadband Services Across Northern California

Comcast California

Comcast announced it will expand its reliable, smart, high-speed, fiber broadband network in both residential and commercial neighborhoods in Northern California’s Marin and Sutter counties. By mid-2026 these expansion efforts will bring Comcast’s next-generation network to over 150 locations in Marin County and over 450 locations in Sutter County, both of which had previously been unserved. This broadband network expansion is made possible by a $14 million Federal Funding Account (FFA) Grant from the California Public Utilities Commission (CPUC) and private funding by Comcast. Comcast also recently announced it has received a $26 million FFA grant to expand its fiber-rich network in Tulare County, which will bring broadband services to nearly 6,200 unserved locations by early 2026. “At Comcast we understand that reliable, high-speed Internet has become a necessity to not only support those looking to participate in the ever-growing digital economy, but also to connect students, families and seniors to those moments that matter the most,” said David Tashjian, Regional Senior Vice President of Comcast California. “This continued investment of funds from the California Public Utilities Commission (CPUC) will allow us to expand into unserved communities throughout Marin and Sutter Counties, which will provide residents and businesses with a future of unlimited possibilities.” “This grant project will help level the playing field for a lot of families in Sutter County who have not previously had access to high-speed Internet,” said Mat Conant, Chair of the Sutter County Board of Supervisors. “This is really important for anyone doing any research for school or work, and for small business owners.” “There has always been an overwhelming demand to improve and expand our broadband services in Marin County,” said Eric Lucan of the Marin County Board of Supervisors. “That need is particularly important for our senior community, including my constituents within a mobile home community in Novato. I commend the California Public Utilities Commission (CPUC) and Comcast on today’s announcement and I’m excited to see the lasting impacts these awards will have in connecting more residents to high-speed Internet and the economic opportunities they will create.” Comcast’s commitment to new communities goes beyond network expansion efforts, addressing digital opportunities in communities through Project UP, the company’s $1 billion dollar commitment to help tens of millions of people connect to the Internet and build futures of unlimited possibilities. Over the past three years, Comcast has invested more than $130 million in cash and in-kind donations into California nonprofits focused on helping people build digital skills, expanding WiFi connected Lift Zones and funding connectivity and Internet adoption programs. Comcast’s funding also supports ongoing efforts to build awareness about affordable connectivity services like Internet Essentials, which offers eligible households high-speed Internet for $9.95/month or Internet Essentials Plus for $29.95/month. Affordable computers are also available through Internet Essentials. Since its inception in 2011, the program has connected more than 2.2 million Californians. Residential customers will be able to take advantage of Xfinity’s full suite of products, including Internet, video, mobile, voice and managed home solutions. For local businesses, Comcast Business will offer a suite of connectivity, communications, networking, cybersecurity, wireless, and managed solutions to help organizations of different sizes prepare for what’s next. Industry analysts and associations have consistently recognized Comcast Business as a leader and innovator, and one of the fastest-growing providers of Ethernet services. Comcast’s network and Internet experience are powering homes today and into the future. Ultimate Capacity: Xfinity customers connect more than 1 billion devices across the company’s network annually. With the next-generation Xfinity gateways, we deliver the most advanced WiFi technology carrying three times more bandwidth to power streaming, gaming, videoconferencing, and more, simultaneously. Fastest Internet: Nearly a third of Xfinity Internet customers subscribe to gigabit speed products. Recently Comcast connected the first customers in the world to a DOCSIS 4.0 connection, delivering symmetrical gig speeds over existing connections in customers’ homes with plans to continue to rollout these speeds across the country over the coming years. Unprecedented Coverage: The latest Xfinity Gateway provides a more reliable connection throughout the home. Customers can get wall-to-wall WiFi coverage with a powerful WiFi Boost Pod that extends coverage to hard-to-reach areas of the home. Most Reliable Connection: Comcast is scaling the nation’s largest and most reliable network that passes 62 million homes and businesses and counting. The company launched Storm-Ready WiFi, a new device that comes powered with cellular and battery backup to help keep customers connected even when the power goes out. Ultra-Low Latency: The Xfinity network and the latest Xfinity Gateway are a powerful combination that deliver ultra-low latency for those moments when response times matter most like video games, a fast-growing category with Xfinity households averaging more than one gaming console per home. For local businesses, Comcast Business will offer a suite of connectivity, communications, networking, cybersecurity, wireless, and managed solutions to help organizations of different sizes prepare for what’s next. Comcast Business has been consistently recognized by industry analysts and associations as a leader and innovator, and one of the fastest-growing providers of Ethernet services. ### About Comcast Business Comcast Business offers leading global businesses the technology solutions and forward-thinking partnership they need. With a full suite of solutions including fast, reliable connectivity, secure networking solutions and advanced cybersecurity and a range of managed service options, Comcast Business is ready to meet the needs of businesses of all sizes. Comcast Business has been recognized by leading analyst firms for its continued growth, innovation, and leadership, and is committed to partnering with customers to help them drive their businesses forward. For more information, call 800-501-6000. Follow @ComcastBusiness on social media networks at http://business.comcast.com/social. About Comcast Corporation Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company. From the connectivity and platforms we provide, to the content and experiences we create, our businesses reach hundreds of millions of customers, viewers, and guests worldwide. We deliver world-class broadband, wireless, and video through Xfinity, Comcast Business, and Sky; produce, distribute, and stream leading entertainment, sports, and news through brands including NBC, Telemundo, Universal, Peacock, and Sky; and bring incredible theme parks and attractions to life through Universal Destinations & Experiences. Visit www.comcastcorporation.com for more information. Contact Details Comcast California Jon Koriel +1 925-315-2690 jon_koriel@comcast.com Company Website https://california.comcast.com/

September 12, 2024 01:46 PM Pacific Daylight Time

Article thumbnail News Release

Flash Transforms Parking at Denver International Airport

Flash

Flash, the leading end-to-end parking technology platform, announced today it has completed an overhaul of public and employee parking at Denver International Airport (DEN) through a contract the City and County of Denver awarded in August 2024. In just 22 days, Flash deployed its platform across the airport’s nine public and employee parking garages and lots, bringing a state-of-the-art parking experience to DEN’s 40,000 employees and the 77.8 million passengers they serve annually. "Flash’s commitment to DEN has been tremendous and we look forward to a bright future that provides innovative solutions to improve the customer experience," said Mark Nagel, Senior Vice President of Parking and Commercial Transportation, Denver International Airport. In its first few weeks of deployment, DEN reports improved traffic flow and reduced wait times for vehicles entering and exiting the airport’s parking facilities. DEN’s deployment of Flash’s platform spans 144 lanes and features 137 kiosks, 97 license plate recognition (LPR) lanes, and 49 automatic vehicle identification (AVI) lanes. With the new AVI lanes, employees can enter and exit automatically in seconds via vehicle-mounted passes that require no interaction with their phones or kiosks. “DEN is the sixth busiest airport in the world and sees millions of parking transactions each year, requiring the highest service level,” said Flash CEO Dan Sharplin. “Our technology breadth and industry-leading scale, plus our maniacal focus on the driver experience, made us confident we could support DEN’s traffic volumes and service levels while getting passengers and employees through parking transactions quickly, and it’s hugely gratifying to see it live.” DEN also benefits from the Flash platform’s design as an enhanced cloud-based parking solution. In the event of an internet, payment processor, network or cloud disruption, the platform maintains continuous operations and critical payment processing capabilities so the airport’s parking facilities stay up and running. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use every day with garage, surface lot, event, and valet parking locations—connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress. The solution has arrived.. Visit www.flashparking.com to learn more. Contact Details Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

September 12, 2024 09:00 AM Central Daylight Time

12345 ... 174